A clinician-oriented summary of what microdosing GLP-1 receptor agonists may do in perimenopause, how it differs from standard dosing, potential benefits and risks, and pragmatic steps clinicians and patients are discussing.
Estrogen decline in perimenopause reduces endogenous GLP-1 signaling, which may worsen hunger, abdominal fat, and glucose control—microdosing can partly replace that signaling.
Combining GLP-1 therapy with hormone therapy, adequate protein intake, and resistance training is a strategy clinicians are using to optimize outcomes and reduce lean mass loss.
It's part of a group of hormones known as incretins, which help regulate post-meal blood sugar levels and influence how satisfied you feel after eating. A quieter, more nuanced conversation is happening in women's health clinics: microdosing these medications during perimenopause. Some physicians are starting patients at 0.05 to 0.1 mg of semaglutide per week, compared to the standard starting dose of 0.25 mg.
Muscle loss is the risk most providers don't warn you about & it's amplified in perimenopause This is the conversation that needs to happen more often. Layer GLP-1-driven appetite suppression on top of that (which naturally reduces protein intake) and the risk compounds. Microdosing, combined with adequate protein intake (25–30g per meal minimum) and resistance training, is one strategy clinicians are using to mitigate this risk.
Jennifer Roelands, M.D., ABOIM September 28, 2026 Contributor By Jennifer Roelands, M.D., ABOIM Contributor Jennifer Roelands, MD, is a double board-certified OB-GYN and integrative medicine expert dedicated to helping women navigate perimenopause, hormone health, and aging with clarity and confidence. GLP-1 is a hormone secreted by the gut when you eat. Here's what the emerging science is telling us.
It's not just about weight loss—this women's health expert explains it all.
There’s more to successful GLP-1 weight loss than watching the scale move.
There’s more to successful GLP-1 weight loss than watching the scale move.
Could GLP-1s be affecting much more than just your appetite?
Randox Health The average person spends 20 years of their life in poor health. Let that sink in. But what if you could avoid that? While there are plenty of zeitgeisty ‘ solutions’ to better health floating around in the ether right now, many of them don’t come with a guarantee. It goes without saying that we’d go out
From readiness, longevity and AI insights to blood tests and movement assessments, we covered everything about the Health app’s redesign.
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.